Amid a widespread industry sell-off, and in the wake of positive trial data from competitor Gilead Sciences (NASDAQ:GILD), shares in AbbVie, Inc (NYSE:ABBV) tumbled by 12.8% last month.

AbbVie is under pressure to overcome looming headwinds tied to the fast-approaching patent expiration on its top selling drug, Humira, but its unclear whether its efforts will succeed. In the following slideshow, I highlight the risks to AbbVie and how it hopes to overcome them. 

 

Why AbbVie Slumped 13% In September from The Motley Fool

Todd Campbell owns shares of Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.